UniProt Q460N5
Protein mono-ADP-ribosyltransferase PARP14 (Q460N5)
Protein mono-ADP-ribosyltransferase PARP14 (UniProt Q460N5), EC 2.4.2.-, 2.4.2.30: 68 experimental structures on GenesisL1, 36 ligands bound, 18 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q460N5
- Protein
- Protein mono-ADP-ribosyltransferase PARP14
- EC
- 2.4.2.-, 2.4.2.30
- Experimental structures
- 68
- Predicted models
- 0
- Ligands
- 36
- Pockets
- 18 · 6 records with a druggable one
Structures
68 records of Q460N5 in the MolNFT archive: 68 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 3GOY | Crystal structure of human poly(adp-ribose) polymerase 14, catalytic fragment in complex with an… | x-ray diffraction | A, B, C, D | — | — |
| 3GOY | Crystal structure of human POLY(ADP-ribose) polymerase 14, catalytic fragment in complex with an… | x-ray diffraction | A, B, C, D | — | — |
| 3Q6Z | HUman PARP14 (ARTD8)-Macro domain 1 in complex with adenosine-5-diphosphoribose | x-ray diffraction | A | — | — |
| 3Q6Z | Human PARP14 (ARTD8)-macro domain 1 in complex with adenosine-5- diphosphoribose | x-ray diffraction | A | — | — |
| 3Q71 | Human parp14 (artd8) - macro domain 2 in complex with adenosine-5-diphosphoribose | x-ray diffraction | A | — | — |
| 3Q71 | Human PARP14 (ARTD8) - macro domain 2 in complex with adenosine-5- diphosphoribose | x-ray diffraction | A | — | — |
| 3SE2 | Human poly(ADP-ribose) polymerase 14 (PARP14/ARTD8) - catalytic domain in complex with… | x-ray diffraction | A, B, C, D | — | — |
| 3SE2 | Human POLY(ADP-ribose) polymerase 14 (PARP14/ARTD8) - catalytic domain in complex with… | x-ray diffraction | A, B, C, D | — | — |
| 3SMI | Human poly(ADP-ribose) polymerase 14 (Parp14/Artd8) - catalytic domain in complex with a… | x-ray diffraction | A, B | — | — |
| 3SMI | Human POLY(ADP-ribose) polymerase 14 (PARP14/ARTD8) - catalytic domain in complex with a… | x-ray diffraction | A, B | — | — |
| 3SMJ | Human poly(ADP-ribose) polymerase 14 (Parp14/Artd8) - catalytic domain in complex with a… | x-ray diffraction | A, B | — | — |
| 3SMJ | Human POLY(ADP-ribose) polymerase 14 (PARP14/ARTD8) - catalytic domain in complex with a… | x-ray diffraction | A, B | — | — |
| 3VFQ | Human PARP14 (ARTD8, BAL2) - macro domains 1 and 2 in complex with adenosine-5-diphosphoribose | x-ray diffraction | A | — | — |
| 3VFQ | Human PARP14 (ARTD8, BAL2) - macro domains 1 and 2 in complex with adenosine-5-diphosphoribose | x-ray diffraction | A | — | — |
| 4ABK | Human PARP14 (ARTD8, BAL2) - macro domain 3 in complex with adenosine- 5-diphosphoribose | x-ray diffraction | A | — | — |
| 4ABK | Human PARP14 (ARTD8, BAL2) - macro domain 3 in complex with adenosine-5-diphosphoribose | x-ray diffraction | A | — | — |
| 4ABL | Human PARP14 (ARTD8, BAL2) - macro domain 3 | x-ray diffraction | A | — | — |
| 4ABL | Human PARP14 (ARTD8, BAL2) - macro domain 3 | x-ray diffraction | A | — | — |
| 4D86 | Human PARP14 (ARTD8, BAL2) - macro domains 1 and 2 in complex with adenosine-5-diphosphate | x-ray diffraction | A | — | — |
| 4D86 | Human PARP14 (ARTD8, BAL2) - macro domains 1 and 2 in complex with adenosine-5-diphosphate | x-ray diffraction | A | — | — |
| 4F1L | Human Artd8 (Parp14, Bal2) - catalytic domain in complex with inhibitor A16(Z) | x-ray diffraction | A, B, C, D | — | — |
| 4F1L | Human ARTD8 (PARP14, BAL2) - catalytic domain in complex with inhibitor A16(Z) | x-ray diffraction | A, B, C, D | — | — |
| 4F1Q | Human Artd8 (Parp14, Bal2) - catalytic domain in complex with A16(E) | x-ray diffraction | A, B | — | — |
| 4F1Q | Human ARTD8 (PARP14, BAL2) - catalytic domain in complex with A16(E) | x-ray diffraction | A, B | — | — |
| 4PY4 | Crystal structure of human poly(ADP-ribose) polymerase 14, catalytic domain in complex with an… | x-ray diffraction | A, B | — | — |
| 4PY4 | Crystal structure of human POLY(ADP-ribose) polymerase 14, catalytic domain in complex with an… | x-ray diffraction | A, B | — | — |
| 5LXP | Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor H5 | x-ray diffraction | A, B | 7AG | — |
| 5LYH | Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor H10 | x-ray diffraction | A, B | 7B8 | — |
| 5NQE | Human PARP14 (ARTD8), catalytic fragment in complex with an N-aryl piperazine inhibitor | x-ray diffraction | A, B | 94Z | — |
| 5NQE | Human PARP14 (ARTD8), catalytic fragment in complex with an N-aryl piperazine inhibitor | x-ray diffraction | A, B | 94Z | — |
| 5O2D | PARP14 Macrodomain 2 with inhibitor | x-ray diffraction | A | 9HH | 2 (best 0.82) |
| 5O2D | PARP14 macrodomain 2 with inhibitor | x-ray diffraction | A | 9HH | — |
| 5QHT | Pandda analysis group deposition -- crystal structure of human PARP14 macrodomain 3 in complex with… | x-ray diffraction | A | CL, GQY | — |
| 5QHU | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, 9KS | — |
| 5QHV | Pandda analysis group deposition -- crystal structure of human PARP14 macrodomain 3 in complex with… | x-ray diffraction | A | CL, AWP | — |
| 5QHW | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, GRV | — |
| 5QHX | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, GRY | — |
| 5QHY | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, GT4 | — |
| 5QHZ | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, GT7 | — |
| 5QI0 | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, GTJ | — |
| 5QI1 | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, GUG | — |
| 5QI2 | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | — | — | — | |
| 5QI3 | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, GUY | — |
| 5QI4 | Pandda analysis group deposition -- crystal structure of human PARP14 macrodomain 3 in complex with… | x-ray diffraction | A | CL, GV1 | — |
| 5QI5 | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, GV4 | — |
| 5QI6 | Pandda analysis group deposition -- crystal structure of human PARP14 macrodomain 3 in complex with… | x-ray diffraction | A | CL, GV7 | — |
| 5QI7 | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, GVV | — |
| 5QI8 | Pandda analysis group deposition -- crystal structure of human PARP14 macrodomain 3 in complex with… | x-ray diffraction | A | CL, GVY | — |
| 5QI9 | Pandda analysis group deposition -- crystal structure of human PARP14 macrodomain 3 in complex with… | x-ray diffraction | A | CL, GW1 | — |
| 5QIA | Pandda analysis group deposition of models with modelled events (E.G. bound ligands) -- crystal… | x-ray diffraction | A | CL, GWA | — |
| 5V7T | Crystal structure of PARP14 bound to N-{4-[4-(diphenylmethoxy)… | x-ray diffraction | A | 91V | — |
| 5V7W | Crystal structure of human PARP14 bound to 2-{[(1-methylpiperidin-4… | x-ray diffraction | A, B | 91J | — |
| 6FYM | Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor ITK1 | x-ray diffraction | A, B, C, D | EBB, NO3 | — |
| 6FZM | Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor ITK6 | x-ray diffraction | A, B | EE5 | 3 (best 0.68) |
| 6FZM | Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor ITK6 | x-ray diffraction | A, B | EE5 | — |
| 6G0W | Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor MCD72 | x-ray diffraction | A, B | EGW | 3 (best 0.65) |
| 6G0W | Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor MCD72 | x-ray diffraction | A, B | EGW | — |
| 6WE2 | Human PARP14 (ARTD8), catalytic fragment in complex with RBN012759 | x-ray diffraction | A, B | XBA | — |
| 6WE3 | Human PARP14 (ARTD8), catalytic fragment in complex with compound 3 | x-ray diffraction | A, B | TZ7, SO4 | 4 (best 0.69) |
| 6WE3 | Human PARP14 (ARTD8), catalytic fragment in complex with compound 3 | x-ray diffraction | A, B | TZ7, SO4 | — |
8 records more on the page itself.
Ligands
- CL · Chloride ion · in 21 records
- 94Z · 3-[[4-[4-(4-fluorophenyl)piperazin-1-yl]-4-oxidanylidene-butanoyl]amino]benzamide · in 2 records
- 9HH · ~{N}-[2-(9~{H}-carbazol-1-yl)phenyl]methanesulfonamide · in 2 records
- EE5 · 4-[(8-methyl-4-oxidanylidene-7-prop-1-ynyl-3~{H}-quinazolin-2-yl)methylsulfanyl]benzoic acid · in 2 records
- EGW · 4-[3-[4-(4-fluorophenyl)piperidin-1-yl]carbonylphenoxy]benzamide · in 2 records
- FDR · 2-methyl-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2, 3-d]pyrimidin-4-one · in 2 records
- SO4 · Sulfate ion · in 2 records
- TYG · 8-methyl-2-{[(pyridin-4-yl)sulfanyl]methyl}quinazolin-4(3H)-one · in 2 records
- TZ7 · 2-{[(trans-4-hydroxycyclohexyl)sulfanyl]methyl}-8-methylquinazolin-4(3H)-one · in 2 records
- XRM · 7-(cyclopentylamino)-5-fluoro-2-{[(piperidin-4-yl) sulfanyl]methyl}quinazolin-4(3H)-one · in 2 records
- 7AG · ~{N}'-(3-aminocarbonylphenyl)-~{N}-[[1-[(2~{R})-2-phenylpropyl]-1,2,3-triazol-4-yl]methyl]pentanediamide · in 1 record
- 7B8 · 3-[2-[4-[2-[[4-[(3-aminocarbonylphenyl)amino]-4-oxidanylidene-butanoyl]amino]ethyl]-1,2,3-triazol-1-yl]ethylsulfamoyl]benzoic acid · in 1 record
- 91J · 2-{[(1-methylpiperidin-4-yl)methyl]amino}-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one · in 1 record
- 91V · N-{4-[4-(diphenylmethoxy)piperidin-1-yl]butyl}[1,2, 4]triazolo[4,3-b]pyridazin-6-amine · in 1 record
- 9KS · N-(2-hydroxyphenyl)acetamide · in 1 record
- AWP · 1-cyclohexyl-3-(2-pyridin-4-ylethyl)urea · in 1 record
- EBB · 7,8-dimethyl-2-(pyrimidin-2-ylsulfanylmethyl)-3~{H}-quinazolin-4-one · in 1 record
- GQY · 2-methoxy-4-morpholin-4-yl-aniline · in 1 record
- GRV · 2-methyl-~{N}-(2-methylpropyl)imidazo[1,2-a]pyridine-3-carboxamide · in 1 record
- GRY · ~{N}1-(4,6-dimethylpyrimidin-2-yl)benzene-1,4-diamine · in 1 record
- GT4 · ~{N}-(4-hydroxyphenyl)-2-methoxy-ethanamide · in 1 record
- GT7 · 2-cyano-~{N}-cyclohexyl-ethanamide · in 1 record
- GTJ · ~{N}-(1-propylbenzimidazol-2-yl)propanamide · in 1 record
- GUG · ~{N}-propan-2-ylquinoline-2-carboxamide · in 1 record
- GUY · ~{N}-(1-propyl-1,2,3,4-tetrazol-5-yl)furan-2-carboxamide · in 1 record
- GV1 · ~{N},~{N},5,6-tetramethylthieno[2,3-d]pyrimidin-4-amine · in 1 record
- GV4 · 2-cyano-~{N}-(1,3,5-trimethylpyrazol-4-yl)ethanamide · in 1 record
- GV7 · 4-[(5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl) amino]phenol · in 1 record
- GVV · ~{N}-(4-methyl-2-oxidanyl-phenyl)propanamide · in 1 record
- GVY · 4-(5-amino-1,3,4-thiadiazol-2-yl)phenol · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.